Header cover image
  • Investing Ideas
  • /
  • Hong Kong Pharmaceuticals & Biotech Large Cap High Growth Potential

Hong Kong Pharmaceuticals & Biotech Large Cap High Growth Potential

Results

1

0 new

Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.

1 companies

WuXi Biologics (Cayman)

Market Cap: HK$83.0b

An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia.

2269

HK$20.50

7D

6.7%

1Y

54.8%